different haematological and biochemical variables are significantly milder in patients on biological therapy, which may limit the utility of classification criteria in this group. Assessment of these findings in larger cohorts is needed.

REFERENCES:

- [1] Schuler GS, et al. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. *Arthritis Care Res* 2018;70:409-19.
- [2] Ravelli A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Ann Rheum Dis* 2016;75:481-9.

Disclosure of Interests: Riccardo Russo Speakers bureau: Novartis, Abbvie, Maria Katsikas: None declared

DOI: 10.1136/annrheumdis-2019-eular.7806

Other orphan diseases

THU0554 THE CLINICAL UTILITY OF TWO VASCULITIS ACTIVITY SCORES(BVAS AND BDCAF) IN BEHÇET'S SYNDROME: A PROSPECTIVE COHORT STUDY

Casandra Buzatu^{1,2}, Stephen Duffield³, Laura Chadwick^{2,3}, Robert J Moots^{2,3}.

¹Research Center of Rheumatic Diseases, Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania; ²Liverpool Behçet's Centre of Excellence, Liverpool, United Kingdom; ³Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom

Background: Behçet's Disease(BD) is a rare chronic autoinflammatory condition that can lead to irreversible organ damage. The potential for multi-organ involvement and fluctuating activity highlights the need to perform a careful and systematic assessment of disease activity that is sensitive to change. Several disease activity tools have been used in both daily practice and clinical trials, yet there is no published data comparing the clinical utility of different tools in informing changes to therapy.

Objectives: To compare the utility of two major activity scores:BD Current Activity Form (BDCAF2006)¹ and Birmingham Vasculitis Activity Score (BVAS)² in predicting physician's decision to adjust treatment (step-up/step-down) in patients with BD.

Methods: A 6-month prospective observational study was performed in a cohort of patients meeting the International Criteria for Behçet's Disease (ICBD),at the National Centre for BD in Liverpool,UK. Participants were described for their demographics, clinical manifestations and treatment plan.BVAS and BDCAF2006 activity scores were completed for each patient at evaluation.The outcome of interest was treatment change which was classified as 'step-up' or 'step-down', reflecting escalation or de-escalation in treatment (dosage adjustment or adding new immunosuppressant), respectively. We assessed the association between BVAS and BDCAF scores and step-up/step-down treatment using Spearman rank correlation and multivariate logistic regressions, adjusting for gender, age and patient's perception of disease activity on visual analogue scale (VAS).Odds ratios(OR) and 95% confidence intervals were calculated. Data analysis was conducted in Microsoft Excel,SPSS 2.0 and STATA.

Results: Ninety-five patients met inclusion criteria: 25 males(26.3%) and 70females(73.7%) with a mean age at diagnosis of 32.7years(±11.3 SD). HLAB51 was positive in 11/51 cases(11.6%).The most frequent clinical manifestations were oral ulcerations(100%), genital ulcerations(94.7%) followed by papulo-pustular skin lesions(37.8%) arthralgia(31.6%)and headache(30.5%).

Mean BVAS score(range 0-6) was 2.14(±1.8 SD) and mean BDCAF score (range 0-8) was 3.04(±1.72 SD). Both BVAS and BDCAF correlated with decision to step-up treatment ($r=0.752$; $r=0.370$, respectively). Furthermore, BVAS was more strongly associated with decision to step-up treatment than BDCAF(OR 4.25 95%CI 2.37 to 7.61; 1.51 95%CI 1.15 to 2.00, respectively). Adjusting for gender, a stronger association was observed in male participants across BVAS and BDCAF scores(OR 5.89 95%CI 1.17 to 29.63; 3.48 95%CI 1.20 to10.09,respectively). Following adjustment for patient's perception of their disease (VAS), BVAS remained significantly associated with treatment step-up(OR 3.87 95%CI 2.08 to7.19) but not BDCAF(OR 1.30 95%CI 0.91 to1.84).

Regarding different clinical manifestations,the BVAS mucocutaneous and ocular activity showed a significant odds ratio for step-up therapy (OR=5.78, CI:1.49-22.15; and OR=4.2,CI: 2.26-7.83).

Conclusion: BVAS can be a useful tool to asses BD activity. In this study, BVAS correlated better with clinical treatment decisions than BDCAF, particularly in male participants. It also appears to be less influenced by patient's subjective perception of disease activity, and therefore may be a more objective measure of BD activity.

REFERENCES:

- [1] International Society for Behçet's Disease, Behçet's Disease Current Activity Form 2006
- [2] Mukhtyar C,et al(2008). "Modification and validation of the Birmingham Vasculitis Activity Score (version 3) *AnnRheumDis*.2008Dec 3.

Acknowledgement: EULAR Scientific Training Bursary

Disclosure of Interests: Casandra Buzatu: None declared, Stephen Duffield: None declared, Laura Chadwick: None declared, Robert J Moots Grant/research support from: Biogen, Bristol-Myers Squibb, Chugai, Novartis, Pfizer Inc, Roche, Sandoz, and UCB, Consultant for: Biogen, Bristol-Myers Squibb, Chugai, Novartis, Pfizer Inc, Roche, Sandoz, and UCB, Speakers bureau: Biogen, Bristol-Myers Squibb, Chugai, Novartis, Pfizer Inc, Roche, Sandoz, and UCB

DOI: 10.1136/annrheumdis-2019-eular.6197

THU0555 10 YEAR PROGNOSIS OF PATIENTS DIAGNOSED WITH FAMILIAL MEDITERRANEAN FEVER

Bugra Han Egeli, Asli Ece Soykut, Bilgesu Ergezen, Serdar Ugurlu. *University of Istanbul- Cerrahpasa, Istanbul, Turkey*

Background: In Familial Mediterranean Fever (FMF), other than amyloidosis factors affecting mortality are being debated. In our previous study, we did not observe any atherosclerotic plaque formation in carotid or femoral artery. We thought that the risk of atherosclerosis did not increase in patients diagnosed with FMF.

Objectives: The aim of this study was to assess the 10 year prognosis and comorbidity of patients diagnosed with FMF who have been treated in our rheumatology clinic.

Methods: The sample group is a subset of 2009 study. In 2009, the patients who already had myocardial infarction or cancer diagnosis were excluded. The patients were interviewed with polar questions of whether they were diagnosed with acute myocardial infarction (AMI), cerebrovascular events, cancer, diabetes, and hypertension.

Results: We studied 71 patients (37 males, 34 females; mean age: 49.66±6.91) with FMF, and 59 patients (24 males, 35 females) in healthy control (HC) group. The gender and age difference between two groups was not found significant.

During 10 year follow-up, 8% of FMF patients had either a cardiovascular or cerebrovascular event comparing to 5% in HC ($p>0.05$). 3% of FMF patients had a cancer diagnosis comparing to 3% in HC ($p>0.05$). Even though diabetes mellitus diagnosis rate was higher in FMF patients (15% to 10%), results were still not significant ($p>0.05$). Hypertension diagnosis was 5% higher in FMF group ($p<0.05$)

Table. Prognostic Factors of FMF patients compared with Healthy Controls

	FMF 2018, n (%)	HC 2018, n (%)	p value
Female	34 (47.89)	35 (59)	0,193
Age	49±6.91	51±5.59	0,076
AMI/Stroke	6 (8.45)	3 (5.08)	0,45
Cancer	2 (2.82)	2 (3.39)	0,85
DM	9 (14.86)	6 (10.17)	0,198
Hypertension	25 (33.78)	10 (16.95)	0,019*
Total	71	59	

Conclusion: Even though there was a significant increase in hypertension, increased diabetes, cancer, and AMI/Stroke ratio was not found significant when compared to the HCs. Therefore, any cardiovascular and malignancy related comorbidities are not associated with FMF.

REFERENCES:

- [1] Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima media thickening in patients with familial Mediterranean fever. *Rheumatology (Oxford)*. 2009 Aug;48(8):911-5.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.4270

THU0556

ARTERIAL AND VENOUS THROMBOTIC EVENTS IN IGG4-RELATED DISEASE: A NATIONAL OBSERVATIONAL RETROSPECTIVE STUDY

Blandine Gutierrez¹, Aurélie Grados², Sylvain Palat¹, Emmanuel Ribeiro³, Noémie Le Gouellec⁴, Julien Haroche⁵, Thomas Papo⁶, Jean-Robert Harlé⁷, Kim Ly¹, Nicolas Schleinitz⁷, Mikael Ebbö⁷, GEFMAG4 (French IgG4-Related Disease Study Group). ¹Limoges University Hospital, Internal Medicine, Limoges, France; ²CH de Niort, Internal Medicine, Niort, France; ³Hôpital Saint-André, Internal Medicine and Clinical Immunology, Bordeaux, France; ⁴CH de Valenciennes, Nephrology, Valenciennes, France; ⁵Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Internal Medicine, Paris, France; ⁶Université Paris-Diderot, Internal Medicine, Hôpital Bichat, Paris, France; ⁷Hôpital de la Timone, AP-HM, Aix-Marseille Université, Internal Medicine, Marseille, France

Background: IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder that can affect virtually every organ. Although arterial involvements have been reported, no studies have examined the occurrence of arterial or venous thrombotic events in these patients.

Objectives: To explore the frequency, the characteristics, and risk factors of arterial and venous thrombotic events in IgG4-related disease patients.

Methods: An observational, descriptive, retrospective study was conducted from a multicentric national case registry for IgG4-RD. Patients fulfilled the Comprehensive Diagnostic Criteria (CDC) for IgG4-RD, and all patients with arterial or venous thrombotic events confirmed by imaging during follow-up were analyzed. Clinical, radiological, biological, histological and therapeutic characteristics were retrospectively collected using a standardized online data sheet. Results obtained in patients with thrombosis were compared to those without thrombosis.

Results: One hundred eighty-nine patients with IgG4-RD (135 men/54 women, median age 61 years) were included. During a 12-months median follow-up, one or more arterial thrombotic events occurred in 10 patients and venous thrombotic events in 16 (5.3 and 8.5 events/100 patient-years, respectively).

Arterial complications (coronary artery disease n=5, lower limb peripheral arterial disease n=2, mesenteric ischemia, transient ischemic attack, and carotid thrombosis: n=1) occurred on average 30 months [0-140] after the first symptoms of IgG4-RD. They were inaugural in 2 patients without any cardiovascular risk factor, and associated with IgG4-RD arterial involvement in 3 (coronary aneurysms n=2, leg arteritis n=1). Among patients with arterial thrombosis, 60% had systemic involvement (≥ 3 organs involved), 89% elevated serum IgG4 (> 3 N in 56%), and 57% CRP > 10 mg/l. Only 5/10 were treated with steroids at the time of arterial complication, and 4 had never been exposed to steroid therapy. Renal involvement was associated with the occurrence of an arterial thrombotic event ($p = 0.03$).

Venous thromboembolic complications (deep venous thrombosis (DVT) n=12, pulmonary embolism n=4) occurred on average 24 months [0-164] after the first symptoms of IgG4-RD, but were inaugural in 6 patients. Usual venous thrombosis risk factors were found in only 3/16. Seven patients had retroperitoneal fibrosis (RPF), 2 had mediastinal fibrosis, 60% had localized IgG4-RD (≤ 2 organs involved), serum IgG4 level was normal in 67% and CRP < 10 mg/l in 79%. Nine patients were on steroids at the time of venous thrombosis. RPF was more frequent in the group of IgG4-RD patients with a venous thrombotic event ($p = 0.05$), and largely associated with DVT in a multivariate analysis (OR=8.36 [2.25-35.93], $p = 0.002$).

Conclusion: Arterial and venous thrombotic complications are common in IgG4-RD patients. While arterial events are associated with multorgan involvement and elevated serum IgG4, venous thrombotic complications appear to affect more likely patients with compressive localized forms of the disease, such as RPF. Mechanisms responsible for this over-risk and clinical benefit of a preventive platelet antiaggregant or anticoagulant treatment in high risk of thrombosis subgroups remain to be evaluated.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.4278

THU0557

NERVE GROWTH FACTOR, SCLEROSTIN AND DKK-1 SERUM LEVELS IN COMPLEX REGIONAL PAIN SYNDROME1 (CRPS-1): A PILOT STUDY ON 41 PATIENTS

Chiara Crotti¹, Maria Manara¹, Francesca Zucchi¹, Davide Gatti², Maurizio Rossini², Massimo Varenna¹. ¹ASST-Gaetano Pini-CTO, Division of Rheumatology, Milan, Italy; ²University of Verona, Department of Medicine, Rheumatology Unit, Verona, Italy

Background: Pain is the hallmark of Complex Regional Pain Syndrome (CRPS). Nerve growth factor (NGF), widely known as pain mediator, is

increased in the affected skin¹ and in tibia bone of rat models of CRPS, while is lowered by administration of anti-NGF antibodies². CRPS usually develops after limb trauma, most frequently a fracture³. Some reports considered bone as a main player in CRPS pathogenesis, hypnotizing that sclerostin (SOST)⁴ and Dickkopf-related protein-1 (DKK-1) may be involved in CRPS pathogenesis.

Objectives: To evaluate NGF, SOST, and DKK-1 serum levels from affected arm of CRPS patients and compare them with unaffected one and healthy controls (HCs).

Methods: Adults patients affected by CRPS diagnosed according to IASP criteria at upper limb were consecutively enrolled from April 2017 to August 2018. Patients with prior treatment with bisphosphonates, and history of disorders of mineral metabolism were excluded. Sera from the basilica vein of affected and unaffected arm of CRPS patients were collected, as well as sera from HCs paired for age and sex. NGF, SOST, and DKK-1 concentrations were determined by ELISA kit. Comparisons between patients and HCs were performed by Student test, while comparison between affected and unaffected arms were performed with Wilcoxon test for paired data. Pearson correlation was used to correlate NGF, SOST, and DKK-1 levels with demographic and clinical variables.

Results: The overall population included 41 patients: males (M) 21.9%, mean age at diagnosis [$\pm$ standard deviation, SD] 61.9 $\pm$ 8.4 yrs, median disease duration 67 days (inter quartile range (IQR) 14.0; 22.5), 39 (95.2%) experienced a fracture as inciting event, mean VAS pain score (0-100) 54.8 $\pm$ 18.6 mm. Mean NGF levels (pg/mL) were 12.0 $\pm$ 28.8 and 11.4 $\pm$ 35.5 in the affected and unaffected side, respectively, and 13.5 $\pm$ 55.0 in HCs. NGF was undetectable in most patients; no statistical significant differences of NGF levels were found between patients and HCs. Mean SOST levels (pmol/L) were 32.6 $\pm$ 16.1, 29.8 $\pm$ 17.7, and 34.0 $\pm$ 13.3 in affected, unaffected arm, and in HCs, respectively. No statistical significant differences of SOST levels were found between patients and HCs, while a significant difference was found between affected and unaffected arms ($p=0.03$). Mean DKK-1 levels (pmol/L) were higher in affected arm (31.2 $\pm$ 29.5) than in unaffected one (29.3 $\pm$ 28.6) or in HCs (27.5 $\pm$ 18.2) without reaching statistical significance. NGF was significantly correlated with VAS pain score ($p=0.04$).

Conclusion: To our best knowledge, this is the first study to evaluate NGF, SOST, and DKK-1 levels in adults affected by CRPS-1. SOST levels were significantly higher in affected arms compared to unaffected ones, suggesting a possible role of this bone mediator in CRPS pathogenesis. NGF was consistent with the expression of pain, through VAS pain score. Further studies need to clarify these preliminary findings.

REFERENCES:

- [1] Li WW, et al. Pain 2010; 151:843–52.
- [2] Sabsovitch I, et al. Pain 2008; 138: 47–60.
- [3] de Mos M, et al. Pain 2007; 129:12-20.
- [4] Robling AG, et al. J Biol Chem 2008;283:5866-75.

Disclosure of Interests: Chiara Crotti: None declared, Maria Manara: None declared, Francesca Zucchi: None declared, Davide Gatti Speakers bureau: Abogen, Amgen, Janssen-Cilag, Mundipharma, Pfizer, Maurizio Rossini: None declared, Massimo Varenna: None declared

DOI: 10.1136/annrheumdis-2019-eular.4855

THU0558

ADULT-ONSET STILL'S DISEASE PROGNOSIS SCORE. CLINICAL PATTERNS, COMPLICATIONS AND BIOLOGIC TREATMENT

Ivette Casafont-Solé¹, Susana Holgado¹, J. Narváez², Maribel Mora², Josep Roca¹, Anahy Brandy-Garcia¹, Lourdes Mateo¹, Melania Martínez-Morillo¹, Laia Gifre¹, Maria Aparicio Espinar¹, Águeda Prior-Español¹, Anne Riveros¹, Clara Sanguesa¹, Jordi Camins-Fàbregas¹, Annika Nack¹, Joan Miquel Nolla², Alejandro Olive¹. ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain; ²Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain

Background: Adult-onset Still's disease (AOSD) is an uncommon disease with an unpredictable clinical course and variable prognosis. Sometimes, it requires biologic treatment in early phases. A prognosis score has been described, which has never been applied in a Spanish case series.

Objectives: To apply the prognosis score described by Pouchot et al (Systemic Score System (SSS)) on a 64 cases series diagnosed with AOSD in Spanish population and to determine if SSS high values registered at the onset of the pathology are related to AOSD clinical patterns (monocyclic, polycyclic and chronic course), requirement of biologic treatment along the disease's course and development of AOSD clinical